IPO Databook: Ionetix (US) - Aug 2026

110 Views09 Aug 2026 10:08

SUMMARY

Ionetix Corporation develops superconducting cyclotron technology for medical and industrial applications, generating revenue from diagnostic and therapeutic radioisotopes.
Superconducting cyclotron technology enables a smaller footprint and cryogen-free operation. Nine sites are FDA-approved for N-13. The global radiopharmaceuticals market is projected to grow to over $26 billion by 2032.
Total revenue was $6,012 in 2025, with diagnostic drug sales at $4,268. The auditor's report includes a "going concern" explanatory paragraph.

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

Try Now

Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:

Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.

Upgrade later to our paid plans for full-access.

SMARTKARMA PREVIEW PASS

By signing up, you agree to our
Terms of Use and Privacy Policy.

Already have an account? Sign In Now

Discussions

(Paid Plans Only)

Price Chart(Sign Up to Access)

Insight Stream